HIV-Env gene DNA allosterism recombination envelope protein antigen for immunoresponsiveness of anti-HIV test and method

An envelope protein, antigen immunization technology, applied in the field of life sciences, can solve problems such as cannot be reviewed one by one, cannot effectively prevent HIV infection, etc.

Inactive Publication Date: 2007-07-25
叶新新
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical human trial results show that gp120 antigen vaccine is not effective in preventing HIV infection
So far, there have been hundreds of clinical human trials of various HIV envelope protein gp120 or gp160 antigen vaccines that have failed, and it is impossible to review them one by one

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] In order to achieve the above object, implement the scheme that the present invention adopts:

[0010] HIV-Env gene DNA Allosteric Recombinant Envelope Protein Antigen Immune Response Anti-HIV Experiment and Method

[0011] 1. Experimental animals and human clinical trials

[0012] 1.1. Experimental animals: 4-6 weeks old germ-free animals, CBA / Ca mice, C57BL / 6 mice or BALB / c mice, Hu-PBL-SCID mice; non-human primates, Rhesus Monkey, gorilla.

[0013] 1.2. Human body for clinical trials: normal healthy people not infected with HIV-I, patients infected with HIV-I in the acute stage.

[0014] 2. Experimental Biomaterials

[0015] 2.1. Rat anti-mouse CD4 receptor monoclonal antibody IgC2a / b - heterogeneous specific ligand antigen of mouse CD4 receptor, simulate HIV-Env gene DNA recombinant envelope protein gp120 or gp160 - human CD4 receptor Rat anti-human or anti-rabbit and other animal monoclonal antibody IgC2a / b - a heterologous antigen that cannot bind to the mous...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A clinic human experiment of HIV envelope protein gp120 or gl160 antigen vaccine proves that it can not prevent the infection of HIV to human body, but can be used to research and screen the anti-HIV therapeutic vaccine and the vaccine for preventing the infection of HIV to human body.

Description

technical field [0001] The invention relates to an HIV-Env gene DNA allosteric recombinant envelope protein antigen immune response anti-HIV experiment and method. It involves the fields of life sciences and medicine. Able to reveal human replication in HIV infection through the envelope protein gp120, a heterospecific ligand for the human CD4 receptor, which interacts with human CD4 + The specific binding of cell-specific receptors first triggers the human immune tolerance mechanism of HIV-infected patients, which has a highly variable immune escape mechanism than HIV, and is more effective against human immunosuppressive pressure. Confirmation: So far, the clinical human trials of all the different HIV envelope protein gp160 and gp120 antigen vaccines designed and developed by scientific research on HIV vaccines cannot prove that they can prevent HIV from infecting humans. One of the most important factors is: HIV envelope The protein gp120 or gp160 is a heterogeneous spec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K49/00G01N33/53G01N33/569
Inventor 叶新新
Owner 叶新新
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap